3/5Mural Oncology plc (MURA): Going-concern doubt

Market data

Price before filing: $2.08 (2025-11-05 close, split/dividend-adjusted)
Market cap at flag: $36.1M (2025-11-06) · Latest: $35.2M (2025-12-09)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: 1 insider sold $15K (1 sale)
30 days after: 1 insider sold $10K (1 sale)

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-08-08 to 2025-12-06. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"Due to the inherent uncertainty in the timing of the Acquisition or other potential strategic alternatives, including impact on its cash consumption, the Company has concluded that as of the date of this Quarterly Report there is substantial doubt about its ability to continue as a going concern."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2025-09-30)

Why this score: quarterly (unaudited) disclosure